Presentation Authors: Aksam Yassin, Karin Sultan Haider, Bremerhaven, Germany, Khalid Alrumaihi, Riadh Alzubaidi*, Sabah Alkadhi, Abdulla Al Ansari, Doha, Qatar
Introduction: ED is a predictive risk factor for CVD. We monitored effectiveness and safety of long-term Testosterone Therapy (TTh) in hypogonadal men with a history of CVD.
Methods: Two observational registry studies of 622 hypogonadal men from two urological centers: 77 men with a previous diagnosis of coronary artery disease (CAD; n=48) and/or a myocardial infarction (MI; n=40) and/or stroke (n=7) received TU for up to 14 years.
Results: Mean age was 60.65 Â± 4.98 years, mean follow-up time was 7.29 Â± 1.20 years. Testosterone (T) levels rose from 9.78 Â± 1.56 nmol/L to trough levels (measured prior to the following injection) between 16 and 18 nmol/L. IIEF-EF (maximum score: 30) increased from 19.64 Â± 6.34 to 24.49 Â± 4.69 with a change from baseline of 5.37Â±0.36, this improvement was statistically significant for the first three years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years.Weight decreased progressively from 114.47 Â± 13.41 to 90.42 Â± 8.77 by 23.6 Â± 0.6 kg, proportion of weight loss: 19.62 Â± 5.71%. Waist circumference decreased from 111.78Â±8.22 to 99.24 Â± 6.48 by 12.51 Â± 0.37 cm. The waist:height ratio improved from 0.64 Â± 0.05 to 0.57 Â± 0.04 (p < 0.0001 for all).Blood pressure (BP, mmHg): Systolic BP decreased from 164.45 Â± 14.4 to 132.96 Â± 8.71, diastolic BP from 99.48 Â± 11.37 to 76.39 Â± 4.89, pulse pressure from 64.97 Â± 6.48 to 56.57 Â± 8.02 (p < 0.0001 for all).Lipid pattern and glycaemic control improved significantly and sustainably. C-reactive protein (CRP) declined from 3.69 Â± 4.51 to 0.25 Â± 0.28 mg/dl.In no patient was testosterone therapy discontinued or interrupted. No cardiovascular events were reported during the observation time.
Conclusions: In hypogonadal men with a history of CVD, T therapy may improve and preserve erectile function for a prolonged period of time. No cardiologic or urologic events observed during entire period of T therapy. TTh appears to be well-tolerated and safe.